登革热候选疫苗TAK-003接种后2年效力研究
首剂后约27个月累积登革热效力为72.7%,住院登革热效力为89.2%;第二年内效力下降至56.2%,4-5岁组下降最明显。
要点
- 首剂后约27个月累积效力72.7%,住院登革热效力89.2%。
- 第二年内效力降至56.2%,4-5岁组下降最明显。
- 效力因血清型而异,血清型优势变化部分解释年度差异。
核心结论
- TAK-003在完成接种后2年内持续降低登革热风险,且不依赖基线血清状态。
- 第二年内效力有所下降,需3年数据判断是否稳定或继续下降。
研究设计与样本
- 通过血清型特异性RT-PCR监测登革热病例。
主要发现
- 首剂后约27个月累积登革热效力为72.7%(95%CI 67.1%-77.3%)。
- 基线血清阴性者效力为67.0%(95%CI 53.6%-76.5%),住院登革热效力为89.2%(95%CI 82.4%-93.3%)。
- 第二年内效力为56.2%(95%CI 42.3%-66.8%),4-5岁组为24.5%(95%CI -34.2%至57.5%)。
- 6-11岁组第二年内效力为60.6%(95%CI 43.8%-72.4%),12-16岁组为71.2%(95%CI 41.0%-85.9%)。
- 第二年内未发生相关严重不良事件。
临床怎么用
- TAK-003可减少登革热发病,尤其降低住院风险,但需关注第二年内效力下降及低龄儿童效力较低。
局限性
- 效力因血清型而异,年度分析受血清型优势变化影响。
- 需3年数据评估效力稳定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Takeda's dengue vaccine is under evaluation in an ongoing phase 3 efficacy study; we present a 2-year update. METHODS: Children (20 099, 4-16 years old) were randomized to receive 2 doses of TAK-003 or placebo 3 months apart and are under surveillance to detect dengue by serotype-specific RT-PCR. RESULTS: Cumulative efficacy against dengue approximately 27 months since first dose was 72.7% (95% confidence interval [CI], 67.1%-77.3%), including 67.0% (95% CI, 53.6%-76.5%) in dengue-naive and 89.2% (95% CI, 82.4%-93.3%) against hospitalized dengue. In the second year, decline in efficacy was observed (56.2%; 95% CI, 42.3%-66.8%) with the largest decline in 4-5 year olds (24.5%; 95% CI, -34.2% to 57.5%); efficacy was 60.6% (95% CI, 43.8%-72.4%) in 6-11 year and 71.2% (95% CI, 41.0%-85.9%) in 12-16 year age groups. As TAK-003 efficacy varies by serotype, changes in serotype dominance partially contributed to efficacy differences in year-by-year analysis. No related serious adverse events occurred during the second year. CONCLUSIONS: TAK-003 demonstrated continued benefit independent of baseline serostatus in reducing dengue with some decline in efficacy during the second year. Three-year data will be important to see if efficacy stabilizes or declines further.Clinical Trials Registration. NCT02747927.Takeda's tetravalent dengue vaccine (TAK-003) continued to demonstrate benefit in reducing dengue independent of baseline serostatus up to 2 years after completing vaccination with some decline in efficacy during the second year in 4-16 year olds in dengue-endemic countries.
引用
- López-Medina E, Biswal S, Saez-Llorens X, et al. Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. J Infect Dis. 2022. PMID: 33319249. doi:10.1093/infdis/jiaa761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。